CN103920081B - 一种药物组合物的用途 - Google Patents
一种药物组合物的用途 Download PDFInfo
- Publication number
- CN103920081B CN103920081B CN201410197004.3A CN201410197004A CN103920081B CN 103920081 B CN103920081 B CN 103920081B CN 201410197004 A CN201410197004 A CN 201410197004A CN 103920081 B CN103920081 B CN 103920081B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- alumen
- camphora
- boric acid
- sophorae flavescentis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 61
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 61
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 61
- 239000004327 boric acid Substances 0.000 claims abstract description 61
- 239000002994 raw material Substances 0.000 claims abstract description 45
- 201000010153 skin papilloma Diseases 0.000 claims abstract description 18
- 208000000260 Warts Diseases 0.000 claims abstract description 15
- 241000700605 Viruses Species 0.000 claims abstract description 12
- 241000701806 Human papillomavirus Species 0.000 claims abstract description 8
- 206010008263 Cervical dysplasia Diseases 0.000 claims abstract description 7
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 claims abstract description 7
- 241001529453 unidentified herpesvirus Species 0.000 claims abstract description 6
- 206010059313 Anogenital warts Diseases 0.000 claims abstract description 5
- 201000001275 rectum cancer Diseases 0.000 claims abstract description 4
- 201000004196 common wart Diseases 0.000 claims abstract description 3
- 201000004303 plantar wart Diseases 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 90
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 66
- 239000010238 camphora Substances 0.000 claims description 60
- 229940025250 camphora Drugs 0.000 claims description 60
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 45
- 238000002360 preparation method Methods 0.000 claims description 43
- 239000000706 filtrate Substances 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 33
- 239000000499 gel Substances 0.000 claims description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- -1 Alumen Chemical compound 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 24
- 239000006228 supernatant Substances 0.000 claims description 24
- 239000000829 suppository Substances 0.000 claims description 20
- 238000001914 filtration Methods 0.000 claims description 18
- 238000010298 pulverizing process Methods 0.000 claims description 18
- 238000004064 recycling Methods 0.000 claims description 18
- 235000019640 taste Nutrition 0.000 claims description 18
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 13
- 108010010803 Gelatin Proteins 0.000 claims description 12
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 12
- 229920000159 gelatin Polymers 0.000 claims description 12
- 239000008273 gelatin Substances 0.000 claims description 12
- 235000019322 gelatine Nutrition 0.000 claims description 12
- 235000011852 gelatine desserts Nutrition 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 11
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 11
- 239000003623 enhancer Substances 0.000 claims description 10
- 239000000080 wetting agent Substances 0.000 claims description 10
- 210000001215 vagina Anatomy 0.000 claims description 9
- 239000000443 aerosol Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 239000007938 effervescent tablet Substances 0.000 claims description 7
- 239000006260 foam Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 239000000003 vaginal tablet Substances 0.000 claims description 7
- 229940044977 vaginal tablet Drugs 0.000 claims description 7
- 239000005711 Benzoic acid Substances 0.000 claims description 6
- 230000002421 anti-septic effect Effects 0.000 claims description 6
- 229960004365 benzoic acid Drugs 0.000 claims description 6
- 235000010233 benzoic acid Nutrition 0.000 claims description 6
- 229960003639 laurocapram Drugs 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 208000001688 Herpes Genitalis Diseases 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 4
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 4
- 201000004946 genital herpes Diseases 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 241001631646 Papillomaviridae Species 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 241000780272 Mammilla Species 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 2
- 241000934136 Verruca Species 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229960004926 chlorobutanol Drugs 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 208000030940 penile carcinoma Diseases 0.000 claims description 2
- 201000008174 penis carcinoma Diseases 0.000 claims description 2
- 229950005134 polycarbophil Drugs 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 abstract description 3
- 244000307697 Agrimonia eupatoria Species 0.000 abstract description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract description 2
- 235000000125 common agrimony Nutrition 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241000922974 Callicarpa bodinieri Species 0.000 abstract 1
- 241000723346 Cinnamomum camphora Species 0.000 abstract 1
- 229940037003 alum Drugs 0.000 abstract 1
- 229960002645 boric acid Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- 229930008380 camphor Natural products 0.000 abstract 1
- 229960000846 camphor Drugs 0.000 abstract 1
- 208000019065 cervical carcinoma Diseases 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 230000001797 effect on sex organ Effects 0.000 abstract 1
- 201000011453 reproductive organ cancer Diseases 0.000 abstract 1
- 208000015608 reproductive system cancer Diseases 0.000 abstract 1
- 208000013013 vulvar carcinoma Diseases 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 62
- 238000000034 method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 6
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229930014456 matrine Natural products 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000003602 anti-herpes Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241001671204 Stemona Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000011951 anti-virus test Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000007859 qualitative PCR Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 组数 | 病毒含量平均值 |
生理盐水组 | 25 | 527237.00±2.38 |
药物1组 | 25 | 3.75±0.41*** |
药物2组 | 25 | 4.43±0.33*** |
药物3组 | 25 | 0.78±0.26*** |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410197004.3A CN103920081B (zh) | 2014-05-09 | 2014-05-09 | 一种药物组合物的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410197004.3A CN103920081B (zh) | 2014-05-09 | 2014-05-09 | 一种药物组合物的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103920081A CN103920081A (zh) | 2014-07-16 |
CN103920081B true CN103920081B (zh) | 2015-01-28 |
Family
ID=51138623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410197004.3A Active CN103920081B (zh) | 2014-05-09 | 2014-05-09 | 一种药物组合物的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103920081B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104758435A (zh) * | 2015-05-05 | 2015-07-08 | 淄博齐鼎立专利信息咨询有限公司 | 中药组合物在制备抗疱疹病毒药物中的应用 |
CN106974884A (zh) * | 2016-01-15 | 2017-07-25 | 贵州双升制药有限公司 | 一种栓剂及其制备方法 |
CN105534879B (zh) * | 2016-01-15 | 2021-06-18 | 贵州双升制药有限公司 | 一种栓剂及其制备方法 |
CN107536971A (zh) * | 2017-09-30 | 2018-01-05 | 张存龙 | 一种治疗疣的外用中药组合物 |
CN108721449A (zh) * | 2018-07-30 | 2018-11-02 | 西安万和医药科技有限公司 | 一种用于抑制hpv感染,有效增强抗hpv感染的凝胶 |
CN112535695A (zh) * | 2019-09-21 | 2021-03-23 | 井冈山市红扁担科技有限公司 | 治疗肠癌的中药提取物组合物、制备方法及其在制备药物中的应用 |
CN114224986A (zh) * | 2021-11-01 | 2022-03-25 | 金中北 | 消杀灵清洗剂 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1879830A (zh) * | 2006-04-29 | 2006-12-20 | 贵州宏奇药业有限公司 | 一种百仙妇炎清泡腾片及其制备方法 |
CN1981858A (zh) * | 2005-12-16 | 2007-06-20 | 杨伟荣 | 一种百草妇炎清凝胶及其制备方法 |
-
2014
- 2014-05-09 CN CN201410197004.3A patent/CN103920081B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1981858A (zh) * | 2005-12-16 | 2007-06-20 | 杨伟荣 | 一种百草妇炎清凝胶及其制备方法 |
CN1879830A (zh) * | 2006-04-29 | 2006-12-20 | 贵州宏奇药业有限公司 | 一种百仙妇炎清泡腾片及其制备方法 |
Non-Patent Citations (1)
Title |
---|
健阴灵栓的研制及临床效果观察;张芳向等;《医学理论与实践》;20050618(第06期);第625页第1栏第1段 * |
Also Published As
Publication number | Publication date |
---|---|
CN103920081A (zh) | 2014-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103920081B (zh) | 一种药物组合物的用途 | |
CN100427082C (zh) | 羟基苯甲酸酯及其类似物在制备预防和治疗病毒性感染药物中的应用 | |
CN103041283B (zh) | 一种外用治疗宫颈hpv感染的中药组合物及其制备方法 | |
CN101254212A (zh) | 美洲大蠊有效部位的用途 | |
CN104353058A (zh) | 商陆抗病毒蛋白冻干粉复合剂及其制备方法 | |
EP3424512A1 (en) | Uses of alginic acid sulfate in preparation of drugs and health care products for preventing and treating diseases caused by human papilloma viruses | |
CN106511512A (zh) | 一种中药外用凝胶及其制备方法与应用 | |
CN102652778A (zh) | 药物组合物 | |
CN102085248B (zh) | 一种治疗宫颈疾病的中药组合物及其制备方法和检测方法 | |
CN113521156B (zh) | 一种中药组合物在制备抗宫颈癌前病变药物中的应用 | |
RU2394586C2 (ru) | Применение скелета клеточной стенки nocardia rubra для получения лекарства против вируса папилломы человека (hpv) | |
CN101791392A (zh) | 药物组合物的用途 | |
CN100428930C (zh) | 对羟基苯甲酸及其类似物在制备预防和治疗皮肤黏膜病毒性感染药物中的应用 | |
CN108042589A (zh) | 片仔癀及其制剂在制备治疗带状疱疹的药物中的新用途 | |
CN100502920C (zh) | 一种治疗尖锐湿疣的中药制剂 | |
CN106177900B (zh) | 一种抗人乳头瘤病毒的凝胶及其制备方法 | |
CN1689591A (zh) | 一种治疗妇科疾病的中药及其制备工艺 | |
CN102688300B (zh) | 药物组合物及其用途 | |
CN102349935A (zh) | 银杏酚酸在制备治疗性病、妇科病和肛周疾病的外用制剂中的用途 | |
CN102652773B (zh) | 药物组合物及其制备方法 | |
CN102058568B (zh) | 吉马酮在制备治疗人乳头瘤病毒药物中的用途 | |
WO2019104587A1 (zh) | 一种药物组合物及其用途 | |
CN101019981A (zh) | 一种中药制剂及其制备方法 | |
CN102512359B (zh) | 一种具有抗疱疹病毒作用的芒果苷乳膏 | |
CN103751105A (zh) | 银杏酚酸纳米脂质体在治疗妇科病和性病中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUIYANG SHUMEIDA PHARMACEUTICAL FACTORY CO., LTD. Free format text: FORMER OWNER: REN MING Effective date: 20150112 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570203 HAIKOU, HAINAN PROVINCE TO: 551400 GUIYANG, GUIZHOU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150112 Address after: Planning area of high-tech industry in Guizhou province 551400 in Qingzhen City Patentee after: Shumeida Pharmaceutical Factory Co., Ltd., Guiyang Address before: 570203 Hainan Province, Haikou City Meilan District Xianqiao 70 road Xianqiao garden building A room 605 Patentee before: Ren Ming |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Planning area of high-tech industry in Guizhou province 551400 in Qingzhen City Patentee after: Guizhou Shuangsheng Pharmaceutical Co. Ltd. Address before: Planning area of high-tech industry in Guizhou province 551400 in Qingzhen City Patentee before: Shumeida Pharmaceutical Factory Co., Ltd., Guiyang |
|
CP01 | Change in the name or title of a patent holder |
Address after: 551400 high tech industrial planning zone, Qingzhen City, Guizhou Province Patentee after: Mingyuan Pharmaceutical Co.,Ltd. Address before: 551400 high tech industrial planning zone, Qingzhen City, Guizhou Province Patentee before: GUIZHOU SHUANGSHENG PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |